RHY 1.00% 9.9¢ rhythm biosciences limited

Ann: Proposed issue of securities - RHY, page-17

ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
  1. 25 Posts.
    lightbulb Created with Sketch. 1
    "Not only would way more people happily submit to the test but the savings to the health industry of having to avoid a boatload of unnecessary colonoscopies"

    Actually, this is incorrect "unnecessary colonoscopies" is driven by the false positive rate that is a function of specificity of the assay. FIT has higher specificity than ColoSTAT (96% versus 91% hence FP rates of 4% and 9% respectively).

    In other words, for every 50K people screened (assuming a CRC prevalence of 0.49%) then FIT will produce ~1,800 FP / unnecessary colonoscopies but ColoSTAT will be ~4,500 unnecessary colonoscopies.
 
watchlist Created with Sketch. Add RHY (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.